Previous Article | Next Article ![]()
Molecular and Cellular Biology, July 2001, p. 4460-4469, Vol. 21, No. 14
Institute of Applied
Biochemistry1 and Center for Tsukuba
Advanced Research Alliance,2 University of
Tsukuba, Tsukuba, Ibaraki 305-8572, Department of Functional
Genomics, Medical Research Institute, Tokyo Medical and Dental
University, Bunkyo-ku, Tokyo 113,3
PRESTO, JST, Kawaguchi, Saitama
332-0012,4 and Institute of Medical
Science, St. Marianna University School of Medicine, Miyamae-ku,
Kawasaki, Kanagawa 216-8512,5 Japan
Received 13 December 2000/Returned for modification 19 January
2001/Accepted 16 April 2001
RNA helicase A (RHA) is a member of an ATPase/DNA and RNA helicase
family and is a homologue of Drosophila maleless protein (MLE), which regulates X-linked gene expression. RHA is also a component of holo-RNA polymerase II (Pol II) complexes and recruits Pol
II to the CREB binding protein (CBP). The ATPase and/or helicase activity of RHA is required for CREB-dependent transcription. To
further understand the role of RHA on gene expression, we have identified a 50-amino-acid transactivation domain that interacts with
Pol II and termed it the minimal transactivation domain (MTAD). The
protein sequence of this region contains six hydrophobic residues and
is unique to RHA homologues and well conserved. A mutant with this
region deleted from full-length RHA decreased transcriptional activity
in CREB-dependent transcription. In addition, mutational analyses
revealed that several tryptophan residues in MTAD are important for the
interaction with Pol II and transactivation. These mutants had ATP
binding and ATPase activities comparable to those of wild-type RHA. A
mutant lacking ATP binding activity was still able to interact with Pol
II. In CREB-dependent transcription, the transcriptional activity of
each of these mutants was less than that of wild-type RHA. The activity
of the double mutant lacking both functions was significantly lower
than that of each mutant alone, and the double mutant had a dominant
negative effect. These results suggest that RHA could independently
regulate CREB-dependent transcription either through recruitment of Pol
II or by ATP-dependent mechanisms.
RNA helicase A (RHA) is a member of
the DExH family of ATPases/helicases and catalyzes the displacement of
both double-stranded RNA and DNA from 3' to 5' (32, 61,
63). Functional domains of RHA include two double-stranded RNA
binding domains at the amino terminus known as dsRBD1 and dsRBD2. The
catalytic core domain is located within the central region and contains
a DExH motif. This core domain contains seven well-conserved motifs; one of them has an ATP binding site with the consensus GCGKT and FILDD,
known as the A site the B site, respectively. The carboxyl terminus
contains an RGG-rich region that is capable of binding single-strand
nucleic acids (62).
RHA was originally isolated as a human homologue of
Drosophila maleless protein (MLE), with which it has 50%
sequence identity and 90% sequence similarity (33). In
Drosophila, MLE colocalizes with acetylated histone H4
(8, 48). MLE is involved in sex-specific gene dosage
compensation and elevates the level of transcription derived from a
single X chromosome in male flies to a level equivalent to that derived
from two X chromosome in the female (25, 29). MLE mutants
are embryonic lethal to males, indicating that MLE is an essential
factor in Drosophila development.
In mammals, RHA-knockout mice are embryonic lethal for homozygous RHA
mutants (35). Analysis of these mice revealed that RHA is
associated with differentiation of the embryonic ectoderm during
gastrulation. It is possible that RHA has an important role in early
embryonic development.
We previously reported that in mammalian cells, RHA functions as a
bridging factor connecting the CREB binding protein (CBP) and holo-RNA
polymerase II (Pol II) complexes (43). CBP is a general
coactivator and plays key roles in nuclear signaling. RHA interacts
with the CH3 domain of CBP via the RHA N terminus and recruits Pol II
through a stretch of 410 amino acids (aa) (positions 255 to 664). RHA
also recruits Pol II to the breast cancer-specific tumor suppressor
protein BRCA1. BRCA1 mutants having a reduced ability to bind to RHA
are observed in breast cancer. It was suggested that the weaker
interaction between RHA and BRCA1 decreases the transcriptional
activity of BRCA1, leading to the development of breast cancer
(4). Recently, RHA was reported to be involved in human
immunodeficiency virus gene expression (19) and
transcriptional regulation of the p16INK4a
promoter (41). These reports indicate that RHA may be an
essential factor for a wide variety of transcriptional pathways.
In addition to its function as a bridging factor, the ATPase
and/or helicase activity of RHA appears to be important for
transactivation. With respect to CREB-dependent transcription, a
lysine-to-arginine change in the ATP binding site of RHA leads to a
loss of ATP binding ability and ATPase activity and results in
decreased transcriptional activity (43). In
Drosophila, the mutant MLE lacking ATPase activity cannot
rescue dosage compensation (34). As ATPase and/or helicase
activity is essential for transactivation, it is likely that both the
sequence and function of these sites are conserved between RHA and MLE.
It is therefore possible that RHA regulates transactivation via common
mechanisms conserved from flies to humans. Investigation of these
mechanisms may shed light on general transactivation mechanisms
conserved in eukaryotic cells. It is not known how RHA can activate
transcription via both an ATP-dependent mechanism and recruitment of
Pol II. The region of RHA containing the previously reported Pol II
binding domain involves helicase motifs; however, there is no motif
reported specifically as a transactivation domain (54).
Accordingly, in this study we have defined a 50-aa minimal
transactivation domain (MTAD) and generated mutants that were not
capable of interacting with Pol II. Furthermore, we also suggest that
RHA could have dual roles in CREB-dependent transcription, based on a
comparison with the mutant lacking ATP binding ability.
Plasmids.
The fragments RHA1, -2, -3, and -4 were obtained
from pGEX-5X-1RHA (1-250), (230-650), (630-1020), and (1000-1279),
respectively (43). The fragments of other RHA deletion
mutants, termed RHA2-1, RHA2-2, RHA2-3, RHA2-4, RHA2-1N, RHA2-1NL,
RHA2-1CL, RHA2-1C, RHA2-1M, RHA2-1NC, MTAD, sMTAD, and cMTAD (Fig.
1A), were generated by PCR-based methods.
The MTAD region of Caenorhabditis elegans (eMTAD) was
amplified from a C. elegans cDNA library by PCR. An alanine
scanning mutagenesis method was used to generate MTAD mutants with
substitutions in each residue conserved among RHA homologues. These
mutants are termed MTADW332A, MTADP334A,
MTADP335A, MTADN338A, MTADW339A,
MTADN340A MTADW342A, MTADN346A,
MTADI347A, MTADD348A, MTADE349A,
MTADL352A, MTADE358A, MTADI360A,
and MTADS361A. Each of these fragments was inserted,
either alone or fused to the GAL4 DNA binding domain (GAL4-DBD), into
pGBT9 (Clontech) or pcDNA3 (Invitrogen) for transactivation assays in
yeast or mammalian cells, respectively. Amino acids 330 to 376 were
deleted from RHA2 to generate RHA2
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.14.4460-4469.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Dual Roles of RNA Helicase A in
CREB-Dependent Transcription
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
MTAD. RHA2 mutations
RHA2W339A, RHA2I347A, and RHA2mATP,
which contains a lysine to-arginine change at position 417 in the ATP
binding site, were generated by PCR. RHA2 mutations, wild-type RHA2,
and MTAD fragments were inserted into pGEX-5X-1 (Amersham Pharmacia
Biotech) for glutathione: S-transferase (GST) pull down and
ATP binding assays. The full-length fragment of wild-type RHA and
mutant with a substitution in the ATP binding site, termed RHAwt and
RHAmATP, respectively, were obtained from each RHA
expression vector (43). The mutated full-length RHA fragments RHA
MTAD, RHAW339A, and
RHAI347A were created by PCR. The double mutant of
full-length RHA (RHAW-mATP) contains the mutations generated in both RHAW339A and
RHAmATP. For transient reporter and ATPase assays,
full-length RHA fragments were introduced into pcDNA3-HA, which was
constructed by inserting hemagglutinin antigen (HA) sequence into
pcDNA3 (39). All plasmids generated by PCR were confirmed
by sequence analysis. The pRc/RSVmCBP, protein kinase A (PKA),
GAL4-CREB (43), and pGAL4 (39) expression vectors, CRE-Luc (59) and pG5b-Luc (60)
reporter plasmids, and control plasmid RSV-
-gal (43)
have been described previously.

View larger version (26K):
[in a new window]
FIG. 1.
Identification of the MTAD of RHA. (A and C) Schematic
representations of RHA and RHA deletion mutants used in transactivation
assays. Solid boxes indicate the functional domains, dsRBD, helicase
motif, and RGG-rich region. Solid bars represent the CBP binding domain
(CBP) and BRCA1 binding domain (BRCA1). The hatched boxes illustrate
MTAD. (B and D) Transactivation assays in yeast. Yeast strain Y190
cells were transformed with RHA deletion mutants inserted into pGBT9 or
empty vector alone. The
-Gal activity derived from cells transformed
with empty vector was designated 1. Each value of relative
-Gal
activity represents the mean ± standard error (n = 3).
Transactivation assay.
Saccharomyces
cerevisiae strain Y190 was transformed with RHA deletion mutants
by a lithium acetate method, and transformants were selected by
incubation on agar plates lacking tryptophan for 3 days. For the liquid
-galactosidase (
-Gal) assay, 1 ml of growth medium was inoculated
with selected colonies. The assay was performed in triplicate to
quantify transcriptional activity of the RHA deletion mutants as
previously described (60).
-Gal activity using
cotransfected RSV-
-gal as a control. Each experiment was performed
in triplicate (14, 45).
Antibodies. Rabbit polyclonal antibodies against the largest subunit of RNA polymerase II (N-20) were obtained from Santa Cruz Biotechnology. Mouse and rat monoclonal antibodies against the HA tag (12CA5 and 3F10) were purchased from Boehringer Mannheim.
GST pull-down assay. The GST fusion protein of each RHA mutant was expressed in Escherichia coli strain TopXF' (Invitrogen) and purified using glutathione-Sepharose beads (Amersham Pharmacia Biotech). Fifty micrograms of nuclear extract obtained from HEK-293T cells was incubated with 2 µg of each GST fusion protein bound to resin in 1 ml of buffer A (20 mM HEPES [pH 7.9], 100 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 0.05% Tween 20, 5% glycerol, 1 mM Na3VO4, 5 mM NaF, 1 µg each of aprotinin, leupeptin, and pepstatin A per ml) for 8 h at 4°C. After washing with buffer A, bound proteins were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and analyzed by Western blotting.
ATP binding assay.
One hundred nanograms of GST fusion
protein bound with beads was incubated with [
-32P]ATP
(5,000 Ci/mmol) in 50 µl of ATP binding buffer (45 mM HEPES [pH
7.6], 0.9 mM EDTA, 0.9 mM EGTA, 4.5 mM magnesium acetate 0.14 mM KCl,
9% glycerol, 0.018% Nonidet P-40, 0.12 mg of bovine serum albumin per
ml) for 10 min at room temperature. ATP was used at a concentration of
2.7 µM. After washing with ATP binding buffer, the bound ATP was
measured by scintillation counting (Coulter) (27).
ATPase assay.
A series of HA-tagged full-length RHA
polypeptides were synthesized in the Promega TNT coupled reticulocyte
lysate system with [35S]-methionine and immunopurified
with anti-HA antibody. Equal amounts of each HA-RHA polypeptide bound
with beads were incubated at room temperature with
[
-32P] ATP (0.5 nCi/reaction, 10 µM ATP [final
concentration]) in 50 µl of ATPase buffer (36 mM HEPES [pH 7.6],
0.05 mM EDTA, 0.05 mM EGTA, 3.6 mM magnesium acetate, 5% glycerol, 50 mM KCl, 0.01% Nonidet P-40). At indicated times, 2 µl of the
reaction was stopped by adding 0.5 µl of 2% sodium dodecyl sulfate.
One microliter of the stopped reaction was spotted onto a
polyethyleneimine-cellulose thin-layer chromatography plate, previously
soaked in ethanol and air dried, and subsequently developed in 0.4 M
K2HPO4-0.7 M boric acid. A bioimaging analyzer
(BAS2000; Fuji) was used to count radiolabeled ATP and Pi
(27, 58).
Transient transfection assay.
Transfection assays were
performed in HEK-293 cells by using calcium phosphate. Cells were lysed
with cell lysis buffer 24 h after transfection, and reporter
activities were measured. Reporter activity was induced by
cotransfection with the PKA expression vector. Recorded activity was
normalized to the protein level of the cell extract, quantified using
the Bradford assay (Bio-Rad) and
-Gal activity from RSV-
-gal. All
experiments were performed in triplicate. HEK-293T cells were
transfected with 100 ng of CRE-Luc or pG5b-Luc reporter plasmid, 50 ng
of wild-type or catalytically inactive PKA expression vector (PKAwt or
PKAmut, respectively), 200 ng of pRc/RSVmCBP or empty vector (pRc/RSV;
Invitrogen), and 0, 50, or 100 ng of full-length RHA expression vector.
For assay with the pG5b-Luc reporter plasmid, cells were cotransfected
with 100 ng of GAL4-CREB expression vector. Cells were cotransfected 50 ng of RSV-
-gal as a control. The total amount of expression vector
was kept constant by adding appropriate amounts of the empty vector
pcDNA3-HA.
| |
RESULTS |
|---|
|
|
|---|
The region between aa 331 and 380 has transcriptional activity. We reported previously that RHA activates CREB-dependent transcription by interacting with Pol II through the region extending from aa 255 to 664 amino acids (43). To further understand the mechanism of transactivation mediated by RHA, we carried out a transactivation assay to identify the transactivation domain. First, to confirm whether the region interacting with Pol II has transcriptional activity, we fused four previously described fragments of RHA, termed RHA1 to -4 (Fig. 1A). GAL4-DBD and quantified their transcriptional activities in yeast. As expected, RHA2, which is known to interact with Pol II (43), activated transcription nine fold more than the vector alone. However, RHA1, -3, and -4 did not activate transcription (Fig. 1B).
To identify the minimal region required for transactivation, RHA2 was divided into four fragments, termed RHA2-1, RHA2-2, RHA2-3, and RHA2-4 (Fig. 1C). RHA2-1 (aa 255 to 380), RHA2-2 (aa 381 to 480), RHA2-3 (aa 431 to 581), and RHA2-4 (aa 531-664) contain the BRCA1 binding domain, helicase motif I and an ATP binding site, helicase motifs II (DEIH) and III, and helicase motifs III and IV, respectively (Fig. 1C). Among these four mutants, only RHA2-1 activated transcription 200-fold more than the empty vector. Subsequent N-terminal deletion mutants of RHA2-1 (RHA2-1CL [aa 282 to 380] RHA2-1C [aa 315 to 380], and MTAD [aa 331 to 380]) were then generated. RHA2-1CL activated transcription comparably to RHA2-1. RHA2-1C and MTAD were also capable of activating transcription 30-fold more than the empty vector, which is less than one-seventh the activation induced by RHA2-1. Independently, the N-terminal and C-terminal halves of MTAD (sMTAD [aa 331 to 361] and cMTAD [aa 362 to 380]) did not activate transcription. All of the mutants lacking the MTADs from RHA2-1, RHA2-1CL, and RHA2-1C (RHA2-1NL [aa 255 to 330], RHA2-1M [aa 282 to 330] and RHA2-1NC [aa 315 to 330], respectively did not activate transcription (Fig. 1C and D). These results suggest that the minimal region for transactivation is this 50-aa region. To examine whether this region functions in higher eukaryotic cells as well as in yeast cells, a reporter assay was performed in HEK-293T cells. A series of deletion mutants fused to GAL4-DBD in a cytomegalovirus promoter-driven expression vector was cotransfected into HEK-293T cells with reporter plasmids containing five GAL4 binding sites upstream of a TATA element. As in yeast, the MTAD was capable of activating transcription in mammalian cells (data not shown). The expression levels of deletion mutants in each experiment were found to be comparable by Western blotting (data not shown). These results show that the minimal region for transactivation of RHA in both yeast and mammalian cells is located between aa 331 and 380.MTAD interacts with Pol II.
We previously reported that the
RHA2 region interacts with Pol II (43). To test whether
MTAD is in fact the Pol II binding region, a binding assay with GST
fusion proteins was performed. MTAD as well as RHA2 interacted with Pol
II, while GST alone did not (Fig. 2). We
conclude that MTAD is the region interacting with Pol II in RHA2.
|
MTAD is well conserved among the RHA homologues. Homologues of RHA have been reported in six species from C. elegans to humans. Comparison of the amino acid sequences of human MTAD and these homologues showed them to be well conserved, particularly within the N-terminal half (Fig. 3A). This prompted us to examine whether the function of MTAD was also conserved among RHA homologues. The transcriptional activity of the C. elegans MTAD (eMTAD), which is the least conserved homologue of RHA, was examined in both yeast and mammalian cells (data not shown). Transcriptional activity of eMTAD fused to GAL4-DBD was 10-fold greater than that of GAL4 alone (Fig. 3B), suggesting a conserved role for MTAD among RHA homologues.
We attempted to identify other proteins that contain this domain. However, using the BLAST sequence alignment program, MTAD was not found in any other proteins, suggesting that MTAD is unique to RHA and distinct from transactivation domains reported previously.Hydrophobic residues are important for transactivation.
The
transactivation domains of some transcriptional factors analyzed
previously tend to be classified according to amino acid composition.
Domains can be classified as acidic, glutamine rich, or proline rich
(54). The MTAD of RHA cannot be classified in this way, as
it has few acidic residues and is not glutamine or proline rich. To
identify the amino acid residues that are important for transactivation
in MTAD, we generated 15 mutants in which residues conserved between
RHA homologues were replaced by alanine by site-directed mutagenesis.
These mutants are referred to as W332A, P334A, P335A, N338A, W339A,
N340A, W342A, N346A, I347A, D348A, E349A, L352A, E358A, I360A, and
S361A (Fig. 3A). These MTAD mutations
were then fused to GAL4-DBD to examine their effects on
transactivation. They are referred to as MTADW332A,
MTADP334A, MTADP335A, MTADN338A,
MTADW339A, MTADN340A
MTADW342A, MTADN346A, MTADI347A, MTADD348A, MTADE349A,
MTADL352A, MTADE358A, MTADI360A, and MTADS361A. As shown in Fig. 1, wild-type MTAD activated
transcription 50-fold more than the empty vector in yeast cells and
140-fold more in mammalian cells. Three mutants with substituted
tryptophan residues, MTADW332A, MTADW339A, and
MTADW342A, were approximately 20% as transcriptionally
active as wild-type MTAD in both yeast and mammalian cells, whereas the
other mutants had levels of activity comparable to that of wild-type
MTAD (Fig. 4A and B). These results show
that the hydrophobic residues in MTAD play an important role in
transactivation.
|
|
MTAD, which have the
region between aa 330 and 376 deleted, did not interact with Pol II
(Fig. 4C). Mutants with other substituted tryptophan residues,
RHA2W332A and RHA2W342A, gave the same result
as RHA2W339A (data not shown), while one mutant
(RHA2I347A) which activated transcription comparably to
wild-type MTAD in the transactivation assay, and another
(RHA2mATP) that had the same activity as the wild type both
interacted with Pol II. These results show that tryptophan residues in
MTAD are important for associating with Pol II.
RHA activates CREB-dependent transcription through MTAD.
To
confirm the contribution of MTAD to RHA-mediated transcription, the
effects of MTAD on CREB-dependent transcription were examined using
reporter assays with full-length RHA mutants
(RHA
MTAD, RHAW339A, and
RHAI347A). These mutants were cotransfected with the CRE-Luc reporter and CBP expression plasmid into HEK-293 cells. In
PKA-stimulated cells, RHAwt activated CRE-Luc 60-fold, and the activity
was further enhanced approximately 1.5-fold with CBP as described
previously (43). In contrast, RHA
MTAD
enhanced activity 18-fold, which is 30% of the activity shown by
RHAwt. Mutants RHAW339A and RHAI347A reduced
activity to 30 and 50% of levels induced by RHAwt (Fig.
5A). The activity induced by
RHAW339A was the same as that induced by
RHA
MTAD. It is therefore clear that MTAD, especially the
tryptophan residues, contributes to CRE-dependent transcription. These
data suggest that the capacity of MTAD to interact with Pol II is
critical to its ability to fully activate transcription.
|
MTAD and RHAW339A to activate
transcription was reduced (Fig. 5B), consistent with results previously
reported for CRE-Luc. Western blot analysis showed that the expression level of these mutants was comparable to the wild-type level (data not
shown). These results suggest that MTAD has an important role in
CREB-dependent transcription.
The W339A mutant has ATP binding and ATPase activities.
As
reported previously, ATPase and/or helicase activities of RHA are
required for CREB-dependent transactivation (43). It is
possible that mutation of hydrophobic residues in MTAD could affect the
ATPase and helicase activities of RHA. Therefore, ATP binding and
ATPase activities of mutants were examined. An ATP binding assay showed
that RHA2mATP had 30% of the ATP binding activity of
RHAwt, while RHA2W339A and RHA2I347A had ATP
binding activity comparable to that of RHAwt (Fig.
6A).
|
MTAD hydrolyzed ATP at a
level comparable to that of RHAwt (Fig. 6B). These results show that the mutations in MTAD had no effect on ATP binding and ATPase activities of RHA.
RHA has dual effects on CREB-dependent transcription.
To test
whether the role of the tryptophan residue at position 339 in MTAD can
be distinguished from ATPase or helicase activity in CREB-dependent
transcription, a double mutant (RHAW-mATP) with a mutated ATP binding site and an alanine substitution for tryptophan at position 339 was generated. The activity of
RHAW-mATP was measured in a reporter assay. As
described above, RHAwt enhanced CREB-dependent transcription in
PKA-stimulated cells. Mutants RHAmATP and
RHAW339A reduced CREB-dependent transcription to 50 and
30%, respectively, of the levels obtained with RHAwt. The double
mutant induced transcription to only 5% of the wild-type level, which
is lower than for each individual mutant. Furthermore, the
transcriptional activity of the double mutant was significantly lower
than that of the empty vector. The double mutant appeared to have a
dominant negative effect on transcription (Fig.
7). Western blot analysis confirmed that
the expression level of each of these mutants is comparable to the
wild-type level (data not shown). These results suggest that RHA could
independently activate CREB-dependent transcription either through
interaction with Pol II or by ATP-dependent mechanisms.
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study, we defined a stretch of 50 amino acid residues between aa 331 and 380 as the MTAD. This domain has transcriptional activity in both yeast and mammalian cells (Fig. 1) and interacts with Pol II (Fig. 2). Sequence analysis revealed that this domain contains six conserved hydrophobic residues unique to the MTAD of RHA homologues (Fig. 3). Mutational analyses indicated that the tryptophan residues are essential for transactivation and Pol II binding of MTAD.
Transactivation domains can generally be classified as acidic, glutamine rich, and proline rich on the basis of amino acid composition. In some cases, it has been shown that hydrophobic residues are important for transcriptional activity (54). Alanine scanning mutagenesis has revealed a role for hydrophobic residues in other acidic transactivation domains from transcription factors such as VP16 (13, 49, 56), RelA (p65) (6, 51), p53 (31, 36, 57), glucocorticoid receptor (2, 3), and GCN4 (24). For VP16 and p53, it was reported that the aromatic residues in particular were important for transactivation, as determined by mutational analysis. Structural analysis also revealed that tryptophan at position 23 in p53 (31) and phenylalanine at position 479 in VP16 (49) were important for interaction with MDM2 and TATA binding protein-associated factor TAFII31, respectively. The importance of tryptophan residues was also reported for Spl and CREB (20, 50). It was suggested that the alternating glutamine and hydrophobic amino acid sequence motifs, which include tryptophan residues, could represent a surface for interaction with TAFs. The MTAD of RHA is neither acidic nor glutamine rich (Fig. 3A), and mutational analysis revealed that a few acidic amino acids were not important for transactivation (Fig. 4A, and B). Therefore, we expect that MTAD may be a novel transactivation domain utilizing hydrophobic residues unique to RHA. Previous studies have reported the presence of CBP and RHA within a holo-Pol II complex (12, 42, 44). In yeast, holo-Pol II complexes contain several components, including Pol II, general transcription factors, the mediator and SWI-SNF complexes, and other proteins (23, 40). Some complexes in mammals including Pol II are homologues of complexes found in yeast (5, 11, 38). In this study, MTAD fused to GAL4-DBD activated transcription in yeast and mammalian cells, even though RHA is not found in yeast. Therefore, we expect that this particular transactivation domain could recruit the general component of holo-Pol II conserved in eukaryotes.
Three tryptophan residues in MTAD are critical for transactivation and
interaction with Pol II (Fig. 4). It remains to be clarified whether it
is hydrophobicity or the aromatic side chain of tryptophan that is
critical for interaction with Pol II. In general, hydrophobic residues
are located within proteins, while polar and charged residues prefer
surfaces. In contrast, tryptophan residues are found on surfaces and in
the interior with nearly identical frequencies. Although tryptophan
residues are comparatively rare, they are statistically most likely to
be found at interfaces (7, 55). This is because tryptophan
can contribute aromatic
interactions, is a hydrogen donor, and has
a large hydrophobic surface (7). It is possible that MTAD
has three tryptophan residues, instead of polar or charged residues,
that enable it to act as an interface on the surface of RHA. However,
the role of the tryptophan residues in MTAD is not understood. The
tryptophan residues may be necessary for maintaining the structure of
MTAD or may be directly involved in the interaction with Pol II. These questions can be addressed by probing the structure of MTAD, using spectroscopic or crystallographic techniques, or by exploring the
association of MTAD with putative target proteins within holo-Pol II complexes.
Our results indicate that the minimal region required for transactivation and Pol II binding is MTAD. However in transactivation assay, RHA2-1 and RHA2-1CL are more active than MTAD. Experiments with RHA2-1NL, RHA2-1M, and RHA2-1NC revealed that there is no additional transactivation domain in RHA2-1 region and activation by RHA2-1 depends on MTAD. There are several explanations, not mutually exclusive, for the higher activity of RHA2-1 and RHA2-1CL. First, the N-terminal region of RHA2-1CL might play a role in stabilization of interaction between MTAD and Pol II. Second, additional factors with no transcriptional activity might bind to the N-terminal region of RHA2-1CL and stabilize the formation of the complex or enhance transcriptional activation by MTAD. Structural analyses of the MTAD and Pol II complex, in combination with investigation into the component of holo-Pol II that interacts with MTAD, are expected to clarify this question.
In a previous study, we showed that RHA could activate CREB-dependent transcription with its ATPase and/or helicase activity (43). Members of the ATPase/helicase family play important roles in many transcriptional processes. They are essential for initiation and transcription-coupled repair and may have important roles in elongation, termination, and transcript stability (16). For example, ATPases/helicases such as TFIIH and the chromatin remodeling complexes participate in transcription, especially in initiation and preinitiation. The enzymatic activities of XPB contained in TFIIH are required for promoter opening (15, 53). It is suggested that the chromatin remodeling complexes, such as SWI-SNF and NURF (nucleosome remodeling factor), could alter chromatin structure with the energy of ATP hydrolysis (22, 26, 52). In addition, MLE, the Drosophila homologue of RHA located within the X chromosome, may be utilized for chromatin remodeling of X-linked genes (34). In a preliminary study, we observed that RHA interacts specifically with the hypophosphorylated form of Pol II (Pol IIA) (S. Aratani and T. Nakajima, unpublished data). It is possible that RHA is involved in preinitiation and/or initiation of transcription. It is tempting to speculate that RHA may contribute to chromatin remodeling and/or transcriptional initiation. However, it is not known which transcriptional activation processes require RHA.
Some factors, e.g., transcriptional regulators such as CREB, CBP, and TFIIH, regulate transcription through dual mechanisms. CREB has bipartite transactivation domains consisting of constitutive and inducible activators, termed Q2 and kinase-inducible domain (KID), respectively (9, 47). The glutamine-rich Q2 domain engages the transcriptional apparatus via a constitutive interaction with human TAFII130 (17, 42). By contrast, the KID region modulates CREB activity via a phosphorylation-dependent association with CBP (10, 46). CBP activates transcription with its histone acetyltransferase activity and functions as a molecular platform for transcriptional activators. It is reported that CREB and STAT1 require both functions of CBP, while nuclear receptors do not require the histone acetyltransferase activity of CBP (28, 30). TFIIH contains two helicases (XPB and XPD) and a kinase (cdk7). Promoters exhibit differential requirements for the kinase activity of cdk7 (1, 53). As described above, it is possible that these transcriptional factors utilize each mechanism differentially according to the situation. In this study, we show that RHA may have dual roles for transactivation. The double mutant lacking the Pol II binding ability and ATP-dependent activity reduced transcription significantly less than each individual mutant (Fig. 7). These results raise the possibility that each function of RHA may be utilized independently in transactivation. In addition, RHA could participate in transcription mediated by several factors. The dual transactivation mechanisms may allow RHA to regulate a broad range of transcription exquisitely in different situations.
| |
ACKNOWLEDGMENTS |
|---|
We thank Noriyuki Hatae for critical discussions. We also thank Yukiko Okada and Megumi Fujita for technical assistance.
This work was supported by grants from the Japanese Ministry of Education, Science, Culture, and Sports (10480196 and 10177230), Japanese Ministry of Health and Welfare, JST (PRESTO), and Human Health Science Foundation and by funds from the Memorial Yamanouchi Foundation, Kaken Pharmaceutical Co. Ltd., and Santen Pharmaceutical Co. Ltd.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Gene Regulation, Institute of Medical Science, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8512, Japan. Phone: 81-44-977-8111, ext. 4113. Fax: 81-44-975-4599. E-mail: nakashit{at}marianna-u.ac.jp.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Akoulitchev, S., T. P. Makela, R. A. Weinberg, and D. Reinberg. 1995. Requirement for TFIIH kinase activity in transcription by RNA polymerase II. Nature 377:557-560[CrossRef][Medline]. |
| 2. | Almlof, T., J. A. Gustafsson, and A. P. Wright. 1997. Role of hydrophobic amino acid clusters in the transactivation activity of the human glucocorticoid receptor. Mol. Cell. Biol. 17:934-945[Abstract]. |
| 3. | Almlof, T., A. E. Wallberg, J. A. Gustafsson, and A. P. Wright. 1998. Role of important hydrophobic amino acids in the interaction between the glucocorticoid receptor tau 1-core activation domain and target factors. Biochemistry 37:9586-9594[CrossRef][Medline]. |
| 4. | Anderson, S. F., B. P. Schlegel, T. Nakajima, E. S. Wolpin, and J. D. Parvin. 1998. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet. 19:254-256[CrossRef][Medline]. |
| 5. | Bjorklund, S., G. Almouzni, I. Davidson, K. P. Nightingale, and K. Weiss. 1999. Global transcription regulators of eukaryotes. Cell 96:759-767[CrossRef][Medline]. |
| 6. |
Blair, W. S.,
H. P. Bogerd,
S. J. Madore, and B. R. Cullen.
1994.
Mutational analysis of the transcription activation domain of ReIA: identification of a highly synergistic minimal acidic activation module.
Mol. Cell. Biol.
14:7226-7234 |
| 7. | Bogan, A. A., and K. S. Thorn. 1998. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280:1-9[CrossRef][Medline]. |
| 8. |
Bone, J. R.,
J. Lavender,
R. Richman,
M. J. Palmer,
B. M. Turner, and M. I. Kuroda.
1994.
Acetylated histone H4 on the male X chromosome is associated with dosage compensation in Drosophila.
Genes Dev.
8:96-104 |
| 9. | Brindle, P., S. Linke, and M. Montminy. 1993. Protein-kinase-A-dependent activator in transcription factor CREB reveals new role for CREM repressors. Nature 364:821-824[CrossRef][Medline]. |
| 10. |
Brindle, P.,
T. Nakajima, and M. Montminy.
1995.
Multiple protein kinase A-regulated events are required for transcriptional induction by cAMP.
Proc. Natl. Acad. Sci. USA
92:10521-10525 |
| 11. | Chao, D. M., E. L. Gadbois, P. J. Murray, S. F. Anderson, M. S. Sonu, J. D. Parvin, and R. A. Young. 1996. A mammalian SRB protein associated with an RNA polymerase II holoenzyme. Nature 380:82-85[CrossRef][Medline]. |
| 12. |
Cho, H.,
G. Orphanides,
X. Sun,
X. J. Yang,
V. Ogryzko,
E. Lees,
Y. Nakatani, and D. Reinberg.
1998.
A human RNA polymerase II complex containing factors that modify chromatin structure.
Mol. Cell. Biol.
18:5355-5363 |
| 13. |
Cress, W. D., and S. J. Triezenberg.
1991.
Critical structural elements of the VP16 transcriptional activation domain.
Science
251:87-90 |
| 14. |
Dorris, D. R., and K. Struhl.
2000.
Artificial recruitment of TFIID, but not RNA polymerase II holoenzyme, activates transcription in mammalian cells.
Mol. Cell. 2Biol.
20:4350-4358 |
| 15. | Drapkin, R., J. T. Reardon, A. Ansari, J. C. Huang, L. Zawel, K. Ahn, A. Sancar, and D. Reinberg. 1994. Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II. Nature 368:769-772[CrossRef][Medline]. |
| 16. | Eisen, A., and J. C. Lucchesi. 1998. Unraveling the role of helicases in transcription. Bioessays 20:634-641[CrossRef][Medline]. |
| 17. |
Ferreri, K.,
G. Gill, and M. Montminy.
1994.
The cAMP-regulated transcription factor CREB interacts with a component of the TFIID complex.
Proc. Natl. Acad. Sci. USA
91:1210-1213 |
| 18. | Foulkes, N. S., E. Borrelli, and P. Sassone-Corsi. 1991. CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell 64:739-749[CrossRef][Medline]. |
| 19. |
Fujii, R.,
M. Okamoto,
S. Aratani,
T. Oishi,
T. Ohshima,
K. Taira,
M. Baba,
A. Fukamizu, and T. Nakajima.
2001.
A role of RNA helicase A in cis-acting transactivation response element-mediated transcriptional regulation of human immunodeficiency virus type 1.
J. Biol. Chem.
276:5445-5451 |
| 20. |
Gill, G.,
E. Pascal,
Z. H. Tseng, and R. Tjian.
1994.
A glutamine-rich hydrophobic patch in transcription factor Sp1 contacts the dTAFII110 component of the Drosophila TFIID complex and mediates transcriptional activation.
Proc. Natl. Acad. Sci. USA
91:192-196 |
| 21. | Hai, T. W., F. Liu, W. J. Coukos, and M. R. Green. 1990. Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev. 4:682. |
| 22. | Hamiche, A., R. Sandaltzopoulos, D. A. Gdula, and C. Wu. 1999. ATP-dependent histone octamer sliding mediated by the chromatin remodeling complex NURF. Cell 97:833-842[CrossRef][Medline]. |
| 23. | Holstege, F. C., E. G. Jennings, J. J. Wyrick, T. I. Lee, C. J. Hengartner, M. R. Green, T. R. Golub, E. S. Lander, and R. A. Young. 1998. Dissecting the regulatory circuitry of a eukaryotic genome. Cell 95:717-728[CrossRef][Medline]. |
| 24. | Jackson, B. M., C. M. Drysdale, K. Natarajan, and A. G. Hinnebusch. 1996. Identification of seven hydrophobic clusters in GCN4 making redundant contributions to transcriptional activation. Mol. Cell. Biol. 16:5557-5571[Abstract]. |
| 25. |
Kelley, R. L., and M. I. Kuroda.
1995.
Equality for X chromosomes.
Science
270:1607-1610 |
| 26. |
Kingston, R. E., and G. J. Narlikar.
1999.
ATP-dependent remodeling and acetylation as regulators of chromatin fluidity.
Genes Dev.
13:2339-2352 |
| 27. | Klemm, R. D., R. J. Austin, and S. P. Bell. 1997. Coordinate binding of ATP and origin DNA regulates the ATPase activity of the origin recognition complex. Cell 88:493-502[CrossRef][Medline]. |
| 28. |
Korzus, E.,
J. Torchia,
D. W. Rose,
L. Xu,
R. Kurokawa,
E. M. McInerney,
T. M. Mullen,
C. K. Glass, and M. G. Rosenfeld.
1998.
Transcription factor-specific requirements for coactivators and their acetyltransferase functions.
Science
279:703-707 |
| 29. | Kuroda, M. I., M. J. Kernan, R. Kreber, B. Ganetzky, and B. S. Baker. 1991. The maleless protein associates with the X chromosome to regulate dosage compensation in Drosophila. Cell 66:935-947[CrossRef][Medline]. |
| 30. |
Kurokawa, R.,
D. Kalafus,
M. H. Ogliastro,
C. Kioussi,
L. Xu,
J. Torchia,
M. G. Rosenfeld, and C. K. Glass.
1998.
Differential use of CREB binding protein-coactivator complexes.
Science
279:700-703 |
| 31. |
Kussie, P. H.,
S. Gorina,
V. Marechal,
B. Elenbaas,
J. Moreau,
A. J. Levine, and N. P. Pavletich.
1996.
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Science
274:948-953 |
| 32. |
Lee, C. G., and J. Hurwitz.
1992.
A new RNA helicase isolated from HeLa cells that catalytically translocates in the 3' to 5' direction.
J. Biol. Chem.
267:4398-4407 |
| 33. |
Lee, C. G., and J. Hurwitz.
1993.
Human RNA helicase A is homologous to the maleless protein of Drosophila.
J. Biol. Chem.
268:16822-16830 |
| 34. | Lee, C. G., K. A. Chang, M. I. Kuroda, and J. Hurwitz. 1997. The NTPase/helicase activities of Drosophila maleless, an essential factor in dosage compensation. EMBO J. 16:2671-2681[CrossRef][Medline]. |
| 35. |
Lee, C. G.,
V. da Costa Soares,
C. Newberger,
K. Manova,
E. Lacy, and J. Hurwitz.
1998.
RNA helicase A is essential for normal gastrulation.
Proc. Natl. Acad. Sci. USA
95:13709-13713 |
| 36. |
Lin, J.,
J. Chen,
B. Elenbaas, and A. J. Levine.
1994.
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.
Genes Dev.
8:1235-1246 |
| 37. | Maekawa, T., H. Sakura, C. Kanei-Ishii, T. Sudo, T. Yoshimura, J. Fujisawa, M. Yoshida, and S. Ishii. 1989. Leucine zipper structure of the protein CRE-BP1 binding to the cyclic AMP response element in brain. EMBO J. 8:2023-2028[Medline]. |
| 38. | Maldonado, E., R. Shiekhattar, M. Sheldon, H. Cho, R. Drapkin, P. Rickert, E. Lees, C. W. Anderson, S. Linn, and D. Reinberg. 1996. A human RNA polymerase II complex associated with SRB and DNA-repair proteins. Nature 381:86-89[CrossRef][Medline]. |
| 39. |
Miyagishi, M.,
R. Fujii,
M. Hatta,
E. Yoshida,
N. Araya,
A. Nagafuchi,
S. Ishihara,
T. Nakajima, and A. Fukamizu.
2000.
Regulation of lef-mediated transcription and p53-dependent pathway by associating beta-catenin with CBP/p300.
J. Biol. Chem.
275:35170-35175 |
| 40. |
Myer, V. E., and R. A. Young.
1998.
RNA polymerase II holoenzymes and subcomplexes.
J. Biol. Chem.
273:27757-27760 |
| 41. |
Myohanen, S., and S. B. Baylin.
2001.
Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter.
J. Biol. Chem.
276:1634-1642 |
| 42. |
Nakajima, T.,
C. Uchida,
S. F. Anderson,
J. D. Parvin, and M. Montminy.
1997.
Analysis of a cAMP-responsive activator reveals a two-component mechanism for transcriptional induction via signal-dependent factors.
Genes Dev.
11:738-747 |
| 43. | Nakajima, T., C. Uchida, S. F. Anderson, C. G. Lee, J. Hurwitz, J. D. Parvin, and M. Montminy. 1997. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90:1107-1112[CrossRef][Medline]. |
| 44. |
Neish, A. S.,
S. F. Anderson,
B. P. Schlegel,
W. Wei, and J. D. Parvin.
1998.
Factors associated with the mammalian RNA polymerase II holoenzyme.
Nucleic Acids Res.
26:847-853 |
| 45. |
Nevado, J.,
L. Gaudreau,
M. Adam, and M. Ptashne.
1999.
Transcriptional activation by artificial recruitment in mammalian cells.
Proc. Natl. Acad. Sci. USA
96:2674-2677 |
| 46. | Parker, D., K. Ferreri, T. Nakajima, V. J. LaMorte, R. Evans, S. C. Koerber, C. Hoeger, and M. R. Montminy. 1996. Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism. Mol. Cell. Biol. 16:694-703[Abstract]. |
| 47. |
Quinn, P. G.
1993.
Distinct activation domains within cAMP response element-binding protein (CREB) mediate basal and cAMP-stimulated transcription.
J. Biol. Chem.
268:16999-17009 |
| 48. | Rastelli, L., and M. I. Kuroda. 1998. An analysis of maleless and histone H4 acetylation in Drosophila melanogaster spermatogenesis. Mech. Dev. 71:107-117[CrossRef][Medline]. |
| 49. |
Regier, J. L.,
F. Shen, and S. J. Triezenberg.
1993.
Pattern of aromatic and hydrophobic amino acids critical for one of two subdomains of the VP16 transcriptional activator.
Proc. Natl. Acad. Sci. USA
90:883-887 |
| 50. |
Rojo-Niersbach, E.,
T. Furukawa, and N. Tanese.
1999.
Genetic dissection of hTAF(II)130 defines a hydrophobic surface required for interaction with glutamine-rich activators.
J. Biol. Chem.
274:33778-33784 |
| 51. |
Schmitz, M. L.,
M. A. dos Santos Silva,
H. Altmann,
M. Czisch,
T. A. Holak, and P. A. Baeuerle.
1994.
Structural and functional analysis of the NF-kappa B p65 C terminus. An acidic and modular transactivation domain with the potential to adopt an alpha-helical conformation.
J. Biol. Chem.
269:25613-25620 |
| 52. | Schnitzler, G., S. Sif, and R. E. Kingston. 1998. Human SWI/SNF interconverts a nucleosome between its base state and a stable remodeled state. Cell 94:17-27[CrossRef][Medline]. |
| 53. | Tirode, F., D. Busso, F. Coin, and J. M. Egly. 1999. Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7. Mol. Cell 3:87-95[CrossRef][Medline]. |
| 54. | Triezenberg, S. J. 1995. Structure and function of transcriptional activation domains. Curr. Opin. Genet. Dev. 5:190-196[CrossRef][Medline]. |
| 55. | Tsai, C. J., S. L. Lin, H. J. Wolfson, and R. Nussinov. 1997. Studies of protein-protein interfaces: a statistical analysis of the hydrophobic effect. Protein Sci. 6:53-64[Medline]. |
| 56. |
Uesugi, M.,
O. Nyanguile,
H. Lu,
A. J. Levine, and G. L. Verdine.
1997.
Induced alpha helix in the VP16 activation domain upon binding to a human TAF.
Science
277:1310-1313 |
| 57. |
Uesugi, M., and G. L. Verdine.
1999.
The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2.
Proc. Natl. Acad. Sci. USA
96:14801-14806 |
| 58. | Weiss, D. S., J. Batut, K. E. Klose, J. Keener, and S. Kustu. 1991. The phosphorylated form of the enhancer-binding protein NTRC has an ATPase activity that is essential for activation of transcription. Cell 67:155-167[CrossRef][Medline]. |
| 59. | Yao, T. P., S. P. Oh, M. Fuchs, N. D. Zhou, L. E. Ch'ng, D. Newsome, R. T. Bronson, E. Li, D. M. Livingston, and R. Eckner. 1998. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93:361-372[CrossRef][Medline]. |
| 60. | Yoshida, E., S. Aratani, H. Itou, M. Miyagishi, M. Takiguchi, T. Osumu, K. Murakami, and A. Fukamizu. 1997. Functional association between CBP and HNF4 in trans-activation. Biochem. Biophys. Res. Commun. 241:664-669[CrossRef][Medline]. |
| 61. | Zhang, S., and F. Grosse. 1994. Nuclear DNA helicase II unwinds both DNA and RNA. Biochemistry 33:3906-3912[CrossRef][Medline]. |
| 62. |
Zhang, S., and F. Grosse.
1997.
Domain structure of human nuclear DNA helicase II (RNA helicase A).
J. Biol. Chem.
272:11487-11494 |
| 63. |
Zhang, S. S., and F. Grosse.
1991.
Purification and characterization of two DNA helicases from calf thymus nuclei.
J. Biol. Chem.
266:20483-20490 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»